Send to

Choose Destination
Urologe A. 2015 Nov;54(11):1578-83. doi: 10.1007/s00120-015-3813-4.

[Testosterone in the management of metastatic prostate cancer].

[Article in German]

Author information

Urologische Klinik, Paracelsus-Klinik Golzheim, Friederich Lau Str. 11, 40747, Düsseldorf, Deutschland.
Kantonsspital St. Gallen, St. Gallen, Schweiz.


Background Among all cancer types, prostate cancer (PCa) is the most prevalent cancer and is the third-leading cause of cancer-related death in men. The biologic function of the prostate is decisively influenced by testosterone and its metabolic product dihydrotestosterone. However, there is general uncertainty about the role of testosterone in metastatic castration-resistant prostate cancer (mCRPC). For many years, the androgen hypothesis had been accepted to explain the correlation between testosterone levels and the development or progression of PCa. However, extensive study analyses revealed contradictory results, leading to a reconsideration of the androgen hypothesis. High serum testosterone levels do not predispose to PCa development and low serum testosterone levels are not protective. The importance of testosterone levels in patients with mCRPC has been shown in several registration studies with new drugs, such as abiraterone acetate and enzalutamide. There is growing evidence suggesting a prognostic role of testosterone levels in mCRPC.


Androgen deprivation therapy (ADT); Castration levels; Prostate cancer; Saturation model; Testosterone levels

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center